Prosecution Insights
Last updated: August 18, 2026
Application No. 17/962,656

Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof

Final Rejection §102§112
Filed
Oct 10, 2022
Priority
Oct 30, 2017 — provisional 62/579,015 +3 more
Examiner
SEAMAN, D MARGARET M
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Regents of the University of Colorado
OA Round
4 (Final)
77%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
1071 granted / 1398 resolved
+16.6% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
42 currently pending
Career history
1420
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
15.9%
-24.1% vs TC avg
§102
19.6%
-20.4% vs TC avg
§112
36.4%
-3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1398 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed 10/10/2022 and is a CIP of 16/760815 (04/330/2020) now US Pat 11466010 which is a 371 of PCT/US18/58286 (10/30/2018) which claims priority to PRO 62/579015 (10/30/2017). RCE papers were filed 12/19/2025 with an amendment and argument. Claims 1-24 are before the Examiner. Response to Amendment The amendment dated 06/29/2026 contains New Matter for claims 1 and 2. Due to this, the following New Grounds of Rejection is warranted. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-2 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Specifically, the amendment to the claims that adds in a proviso… “and wherein when R1 is -OH, R4 is alkoxy” for both claims 1 and 2 is not specified in the instant specification. This is a new matter rejection. If this New Matter is removed from the claims 1 and 2, then the following rejection from the previous office action dated 12/29/2025 would be upheld. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The rejection of claims 1, 2, 4 and 8 under 35 U.S.C. 102(a)(1) as being anticipated by Zhang, as stated in paper dated 09/30/2025, is upheld. Specifically on page 62 PNG media_image1.png 170 156 media_image1.png Greyscale second compound where R=OH anticipates the instant claims. This compound fully anticipate the instant claims. Applicant argues in paper dated 12/19/2025 that the amendments to claim 1 overcome the rejection of record. However, that is not the case. The two compounds taught by Zhang where the above pictured R is OH anticipates the instant claims. For the instant claims 1, 2, 4 and 8…X=C, X’=N, R1is OH, R2, R3 and R5=H and R4=OH. The proviso in claim 1 reads…when R1is either H or alkoxy then R4 is alkoxy. However, R1=OH is not within the scope of the proviso since R1 is neither H or alkoxy. Due to this, the rejection is upheld. Claim Objections Claims 3-12 (with the New Matter rejection) are objected to because of the following informalities: These claims depend from a rejected base claim but would be allowable if rewritten in independent form free of the above cited rejections. Appropriate correction is required. Allowable Subject Matter Claims 13-24 are free of prior art and are allowed. Conclusion Applicant's amendment (dated 06/29/2026) necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D MARGARET M SEAMAN whose telephone number is (571)272-0694. The examiner can normally be reached M-F 8am-4pm Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Show 1 earlier event
Jun 13, 2025
Non-Final Rejection mailed — §102, §112
Sep 13, 2025
Response Filed
Sep 30, 2025
Final Rejection mailed — §102, §112
Dec 19, 2025
Request for Continued Examination
Dec 22, 2025
Response after Non-Final Action
Dec 29, 2025
Non-Final Rejection mailed — §102, §112
Jun 29, 2026
Response Filed
Jul 16, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692235
FUSED RING COMPOUND AND APPLICATION THEREOF
4y 0m to grant Granted Jul 28, 2026
Patent 12692276
TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS
3y 1m to grant Granted Jul 28, 2026
Patent 12686665
BICYCLIC FUSED RING DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
2y 3m to grant Granted Jul 21, 2026
Patent 12679828
METHOD FOR PREPARING LIFITEGRAST
4y 1m to grant Granted Jul 14, 2026
Patent 12679814
SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS
3y 1m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
77%
Grant Probability
85%
With Interview (+8.0%)
2y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1398 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month